Commercially available disopyramide is a racemic mixture of equal parts of dextrorotatory (d-) and levorotatory (1-) optical isomers. We studied the cardiac effects of i.v. adnministration of each isomer and the racemic mixture (dl-) in six normal males by digitized echocardiography, systolic time intervals and ECG. Both isomers and the racemic mixture produced equally marked dose-dependent negative inotropic effects (28.1 11.8% mean maximal reduction in fractional shortening of left ventricular dimension) and diastolic effects (28.6 + 24.1% mean maximal reduction in peak left ventricular filling rate). Howevet, only the d-isomer prolonged QTc duration (by 13.6 5.2% at maximum, p < 0.001 vs 1-isomer).
mately 1 week apart, a 1.5-mg/kg i.v. dose of either d-, 1or dl-(racemic) disopyramide was infused over 10 minutes. One patient received the d-and 1-isomers but not the racemic mixture. Blood pressure, ECG, Mmode echocardiography of the left ventricle, systolic time intervals, and blood samples were taken at all or some of the following time periods: -30, -20, - 10, 5, 15, 30, 45, 60, 120 , and 180 minutes (0 minutes start of infusion).
Echocardiographic Studies
M-mode echocardiograms of the left ventricle were recorded at 100 mm/sec with a 2.25-MHz transducer and Irex system II echocardiograph. The echocardiograms were digitized and the following standard measurements in diastole and systole were obtained: left ventricular internal dimension, interventricular septal thickness, and left ventricular posterior wall thickness. In addition, the peak rates of change (d/dt) of the left ventricle, interventricular septum and posterior wall were obtained for both diastole and systole. 14 Three to five beats were analyzed and averaged for each time period (nine to 15 beats before infusion).
Systolic Time Intervals
Systolic time intervals were calculated from the simultaneous recording at 100 mm/sec of ECG lead IL, carotid pulse using a hand-held transducer, and phonocardiogram from a microphone placed parastemally over the second right intercostal space. Left ventricular ejection time (LVET) and preejection period (PEP) were derived.'5 Three cycles were measured and averaged for each period.
Electrocardiogram A 12-lead ECG was performed at each period. In three patients the ECG was obtained using the Hewlett Packard 5600C ECG management system. PR, QRS and QT intervals were derived by computer in these three patients and determined from an average of all 12 447 VOL 66. No 2, AUCiUST 1982 leads. In the three patients without computer-recorded ECGs, the intervals were measured from lead II recorded at 100 mm/sec.
Blood Samples
Disopyramide concentrations in plasma were determined by high-pressure liquid chromatography"3 by modification of the procedure of Illett et al. '6 Statistical Methods
We compared the differences of the average of the data for d-, 1-and dl-disopyramide obtained in the first hour after the drug infusion (5, 15, 30, 45 and 60 minutes) minus the average of all data obtained at -30, -20, and -10 minutes (control). The differences were compared by analysis of variance for randomized blocks. The t test for paired data was used to compare each period with control.
Results

Echocardiographic Studies
The concentrations of d-, 1-and dl-disopyramide were similar during the time the cardiac measurements were determined. Thus, the data obtained after administration of the three compounds can be compared directly with respect to time and do not have to be normalized with respect to concentration. A detailed pharmacokinetic analysis will be presented in a future publication.
The effects of disopyramide on left ventricular echocardiographic standard dimensions and peak rates of change are shown in tables 1 and 2. No differences in any of the echocardiographic measurements were observed comparing the isomers. Thus, the mean of all three studies is expressed as a percent change from control. In the dimensions that were altered by disopyramide there were significant differences compared to control, up to and including 60 minutes but not at 120 or 180 minutes. Maximal changes were seen at 15 minutes. (table 1) Fractional shortening of left ventricular dimension was maximally reduced by 28.1 + 11.8% (mean ± SD) (p < 0.001) (figs. 1 and 2). There was little significant change in left ventricular internal dimension in diastole, but left ventricular internal dimension in systole increased maximally by 13.8 + 6.9% (p < 0.001). There was little change in interventricular septal thickness in diastole or in posterior left ventricular wall thickness in diastole. However, interventricular septal thickness in systole was maximally reduced by 12.6 + 11.9% (p < 0.001) and posterior wall thickness in systole was maximnally reduced by 8.0 ± 10.1% (p < 0.001).
Standard Dimensions
Peak Rates of Change (table 2) Peak left ventricular emptying rate was maximally reduced by 18 .0 + 12.4% (p < 0.001) and peak left ventricular filling rate was maximally reduced by 28.6 ± 25.1% (p < 0.001) (figs. 1 and 3). Peak rate of septal diastolic thinning was not significantly changed but peak rate of septal systolic thickening was maximally reduced by 16.7 ± 17. 1 % (p < 0.0 1). Peak rate of posterior wall systolic thickening and diastolic thinning were both reduced maximally by 19 .5 + 20.9% and 32.9 ± 24.7% respectively (p < 0.001).
Systolic Time Intervals (table 3) No differences in the effect on systolic time intervals were detected between the isomers. The mean of all three studies is expressed as a percent change from control. There were significant changes compared with the control up to and including 60 minutes but not at 120 or 180 minutes. Maximal changes were seen at 15 minutes. The PEP was maximally prolonged by 26.8 ± 10.4% (p < 0.001). The left ventricular ejection time was maximally reduced by 6.4 + 2.9% (p < 0.001). The PEP/LVET was maximally increased by 36.0 ± 15.0% (p < 0.001).
PR and QRS Intervals (table 4)
There was no difference between the isomers in the mean change of PR or QRS duration over the first hour. Combining the three studies, PR was prolonged maximally at 15 minutes by 8.5 + I; I and QRS was prolonged maximally at 15 minutes by 3.7 ± 5.5% (p < 0.01). Values were not different from control at 120 or 180 minutes.
Heart Rate (table 4) Combining the three studies, there was a significant decrease in heart rate only at 5 minutes of 7.0 ± 10.6% (p < 0.05) and a significant increase in heart ratecnly at 15 minutes of 5.6 ± 8.4% (p < 0.05). The three isomers were also analyzed separately. Heart rate was reduced with the 1-isomer by 9.7 ± 5.8% at 5 minutes (p < 0.05) and was increased by 0.7 + 7.2% at 15 minutes (NS). Heart rate was reduced with the disomer by 2.6 + 15.7% at 5 minutes (NS), but increasedby 11.7 ± 9.7% at 15minutes(p <0.05). The differences between the isomers were not statistically significant.
Blood Pressure (table 4) There was no difference between the isomers in the effect on blood pressure. Combining the three studies, systolic blood pressure did not change significantly, but diastolic blood pressure increased from 5 minutes through 60 minutes. The maximal increase of 11.7 ± 8.2% occurred at 15 minutes (p < 0.001).
QT anid QTc Intervals (table 5) The effects on the QT and QTc interval were different between the isomers (p < 0.001) ( fig. 4 ). With the d-isomer, the QTc was significantly prolonged at 5 minutes and all time intervals up to and including 180 minutes, and was maximally prolonged at 15 minutes, by 13.6 ± 5.2% (p < 0.01). With the 1 -isomer, there was no significant prolongation of QTc. With the dlracemic isomer, the QTc was maximally prolonged at 15 minutes, by 6.5 ± 2.8% (p < 0.01). 
Drug Concentration
There was no significant difference in plasma drug concentrations between the isomers. The mean drug concentrations for each time period are shown in table 6 . There was a significant correlation between the percent change in fractional shorteninig of left ventricular dimension and mean drug concentrations in the first hour (r = 0.87, p < 0.01) and between the percentage change in QTc and mean drug concentrations up to 180 minutes (r = 0.95, p < 0.001) (Giacomini KM, Pollick C, Pershe R, Popp RL, Blaschke TM: manuscript in preparation).
Discussion
Disopyramide may effectively suppress both ventricular and supraventricular arrhythmias,7 but by its negative inotropic action may also precipitate heart failure4 I and cardiogenic shock.6 Studies of patients with heart disease have shown a 6-30% decrease in cardiac output,182-3 a 12-25% decrease in left ventricular dP/dt max,' P a 17-33% decrease in ejection frac-tion3 24and a 25-40% increase in PEP/LVET.5 26Previous studies in normal subjects"',n 2 have shown relatively little myocardial depression. Yu"8 stated that i.v. disopyramide in a dose of 1.5-2 mg/kg produces no measurable hemodynamic effect in patients with normal left ventricular function.
Disopyramide markedly depressed left ventricular function measured echocardiographically in normal subjects. This effect was independent of the optical rotation of the isomer. The reduction in fractional shortening was brought about by a larger end-systolic diameter, without any change in end-diastolic diameter. Our findings are in agreement with those of Martin et al.,29 who studied four normal subjects and observed a 33.3% maximal decrease in fractional shortening and 17.6% maximal increase in end-systolic diameter during a high-dose steady-state disopyramide infusion.
The cause of the myocardial depressive effects of disopyramide is unclear, but this study has deinonstrated that it is independent of optical rotation. Quinidine, which acts in a similar manner, depresses mitochondrial calcium transport, respiration and oxidative phosphorylation.30 Disopyramide in a guinea pig heart muscle preparation produced a dose-dependent reduction in superficial calcium stores."' However, the role of these mitochondrial changes in producing the cardiodepressent effects is unclear.3 Whether the cellular mechanism of myocardial depression is the same or different from that which produces electrophysiologic effects is also unclear. 0 Our data and previous data&6 show a good correlation between blood levels of disopyramide in the first hour of administration and myocardial depression as demonstrated by reduction in fractional shortening (r 0.85, p < 0.01). In a previous study of seven patients with cardiac disease,e6 PEP increased by 10% when the serum disopyramide level was 3.8 + 1.5 ,ug/ ml (range 2.0-5.7 ,tg/ml). In this study there was still evidence of myocardial depression at 60 minutes when the disopyramide level was 3.13 ± 1.4 /g/ml, but not at 120 minutes, when the drug level was barely different, 2.92 + 1.2 gg/ml. The myocardial depression at 60 minutes represented partial recovery of function, and contractility returned to control values at 120 minutes.
Systolic arterial pressure did not change, but mean diastolic pressure increased 11.7 ± 8.2%. This result can probably be explained by the increase in peripheral resistance that accompanies disopyramide administration. 32 The small increase in afterload associated with the increase in diastolic pressure may have partially contributed to the reduction in fractional shortening.
Despite the relatively frequent precipitation of pulmonary congestion and pulmonary edema in patients with heart disease,4 previous studies of disopyramide have shown no or little effect on the diastolic properties of the left ventricle, as evidenced by 0-5 mm Hg increase in left ventricular end-diastolic pressure or pulmonary capillary wedge pressure.5 19-21 33 34 However, we found a marked reduction in the peak left ventricular filling rate that was independent of optical rotation. Peak filling rate was maximally reduced by 28.6 ± 24.1% at 15 minutes. This was accompanied by a 32.9 ± 24.7% reduction in the posterior wall thinning rate. The decrease in peak filling rate may be related to the increase in end-systolic dimension after disopyramide administration, as left ventricular relaxation, as measured by peak negative dP/dt, has been negatively correlated with end-systolic dimension.35 However, in a recent radionuclide angiographic study36 of 11 patients with coronary artery disease, propranolol reduced peak ejection rate by 16% and did not change peak filling rate, and verapamil decreased ejection fraction by 8% from control values but increased peak filling rate by 21%. This suggests that the diastolic consequences of disopyramide could be independent of its negative inotropic properties and consequent effects on end-systolic dimension.
The effects of disopyramide on the ECG have been noted since 19611. 2 and include increases in the duration of the PR, QRS and QT intervals in normal subjects and in patients with heart disease. We have demonstrated a mean maximal increase in the PR interval of 8.5 + 8.9% and a mean maximal increase in QRS duration by 3.7 + 5.5%. Electrophysiologic studies with disopyramide have demonstrated an increase in atrioventricular conduction time37 and His-Purkinje time33 to account for these changes on the surface ECG. Previous studies with disopyramide have shown either no change, a slight decrease, or a slight increase in heart rate. 3 In our study group, there was a significant small decrease in heart rate at 5 minutes and a small increase at 15 minutes. The initial slowing is probably due to a direct depressant effect on the sinus node and the later increase in heart rate to the drug's anticholinergic effect.37 Heart rate increased at 15 minutes with the d-isomer but did not significantly increase with the 1-isomer. This observation coincides with studies on guinea pig ileum in which the d-isomer had three to four times the anticholinergic activity of the 1-isomer. 12 The mean maximal increase in the QTc interval with the d-isomer was 13.6 + 5.2% and the 1-isomer was 3.0 + 3.5% (p < 0.001). The prolongation of QTc was related to the drug concentration (r -0.95, p < 0.001). However, unlike the depression of contractility, there was persistent prolongation of QTc by the disomer at 120 and 180 minutes, suggesting different thresholds for the electrical mechanical effects. The reason for the difference between the isomers and the effect on the QT interval is unclear. There is sparse parasympathetic innervation of the left ventricular myocardium3" and atropine does not significantly influence the refractoriness of right ventricular muscle. 39 Therefore, it is unlikely that the different anticholinergic potencies of the isomers demonstrated in vitro"2 are related to the differences in QTc effects. Disopyramide decreases the amplitude and maximum upstroke velocity of the transmembrane action potential, widens the action potential, and prolongs the ventricular refractory period in vitro.40 4' These last two effects may account for the prolongation of the QT interval which, as with quinidine, probably should be considered a disopyramide effect rather than a toxic reaction.43 Thus, the prolongation of the QT interval may be an indicator that the drug is functioning therapeutically as an antiarrhythmic agent. If so, the 1-isomer may have fewer antiarrhythmic properties. Alternatively, the electrophysiologic effects responsible for the antiarrhythmic properties may be separate from the effects on the QT interval, and therefore the 1-isomer may be just as effective as the d-isomer. The excessive prolongation of the QT interval has been associated with malignant ventricular arrhythmias7-9 and electromechanical dissociation. 43 The lack of effect of the 1isomer on the QT interval, therefore, may have therapeutic advantages.
The clear difference between the isomers with respect to the effect on the QT interval without a concomitant difference in the negative inotropic activity, and the apparent difference in drug threshold between the two effects, suggest that the cellular mechanisms of some of the electrophysiologic effects of the drug and the myocardial depressant effects are different. Thus, -p < 0.001 vs control. Abbreviations: Cc = combined drug concentration of all three studies (n 17); AFS combined difference in fractional shortening from control (n = 17); Cd = d-isomer drug concentration (n = 6); AQTc = difference in QTc duration from control for d-isomer (n = 6).
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one may define a form of the disopyramide compound that does not possess negative inotropic properties, but which is nevertheless antiarrhythmic.
